Current Report Filing (8-k)
July 20 2022 - 3:47PM
Edgar (US Regulatory)
0000720154
false
0000720154
2022-07-15
2022-07-15
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
Date of Report (Date of earliest event reported):
July 15, 2022
INOTIV, INC. |
(Exact name of registrant as specified in its charter) |
Indiana |
|
0-23357 |
|
35-1345024 |
(State or other jurisdiction of
incorporation) |
|
(Commission File Number) |
|
(IRS Employer Identification No.) |
2701 KENT AVENUE
WEST LAFAYETTE, indiana |
|
47906-1382 |
(Address of principal executive offices) |
|
(Zip Code) |
Registrant's telephone number, including area code: (765) 463-4527
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title
of each class |
Trading Symbol(s) |
Name of each
exchange
on which registered |
Common Shares |
NOTV |
The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth
company ¨
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
| Item
7.01. | Regulation
FD Disclosure. |
On July 18, 2022, Inotiv, Inc. (the “Company”)
issued a press release announcing that its subsidiary, Envigo RMS LLC (“Envigo”), has entered into a settlement with
the U.S. Department of Justice (“DOJ”) and the U.S. Department of Agriculture (“USDA”) that resolves an extensive
civil and administrative investigation into Envigo’s facility in Cumberland, VA (the “Cumberland Facility”).
The settlement, which was mutually entered into
by all parties involved and approved by the court on July 15, 2022, does not require that Envigo pay any fines or penalties to governmental
agencies. In addition, it is expressly stated that the settlement is not an admission of liability or wrongdoing by Envigo with regard
to its past operation of the Cumberland Facility. The resolution incorporates the transfer plan that was mutually agreed to by the DOJ
and Envigo on July 1, 2022 (the “Transfer Plan”), and it concludes all related civil and administrative complaints related
to the Cumberland Facility. In addition, the settlement requires that the DOJ and USDA move to dismiss the civil and administrative complaints
with prejudice seven days after all the canines vacate the Cumberland Facility pursuant to the Transfer Plan.
A
copy of the above-referenced press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated
herein by reference. This information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange
Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the
Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
| Item
9.01. | Financial
Statements and Exhibits. |
This document may contain forward-looking statements
that are subject to risks and uncertainties including, but not limited to, risks and uncertainties related to changes in the market and
demand for our products and services, the development, marketing and sales of products and services, changes in technology, industry and
regulatory standards, the timing of acquisitions and the successful closing, integration and business and financial impact thereof, governmental
regulations, inspections and investigations, settlement matters, expansion and related efforts, and various other market and operating
risks, including those detailed in the Company's filings with the U.S. Securities and Exchange Commission.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto
duly authorized.
|
INOTIV, INC. |
|
|
|
|
|
|
Date: July 20, 2022 |
By: |
/s/ Beth A. Taylor |
|
|
Chief Financial Officer, |
|
|
Vice President—Finance |
Bioanalytical Systems (NASDAQ:BASI)
Historical Stock Chart
From Jun 2024 to Jul 2024
Bioanalytical Systems (NASDAQ:BASI)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Bioanalytical Systems Inc (NASDAQ): 0 recent articles
More Inotiv, Inc. News Articles